Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias

This study has been completed.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Nikhil Munshi, M.D., Boston VA Research Institute, Inc. Identifier:
First received: January 14, 2014
Last updated: April 10, 2016
Last verified: April 2016

This is a research study to determine if the study drug lenalidomide will increase the body's immune response, which is the body's response against infections or tumors, to hepatitis B vaccine in patients with plasma cell diseases which include multiple myeloma, monoclonal gammopathy of unknown significance (MGUS) and Waldenström's Macroglobulinemia. It is not a study to see if lenalidomide is an effective treatment for plasma cell disease.

Participants in this study have multiple myeloma or other plasma cell disease and have never been vaccinated with hepatitis B vaccine. One of the effects of the drug lenalidomide is to alter the immune system and thereby increase immune response. It also has some effect against cancer cells; therefore, in theory, it may reduce or prevent the growth of cancer cells.

In this study, one-half of the subjects will be chosen at random to receive the study drug and the other half will take a placebo pill (a sugar pill that looks the same as the real medication). This is a double blind study where neither the subjects nor the investigators know whether the patient receives the study drugs or placebo pills. The effects of the active drug lenalidomide will be compared to the effects of the placebo. The results from this study will be also be compared with a similar but separate study to be done on individuals without known disease.

This study expects to enroll 64 subjects and will be carried out at the Boston VA Healthcare System and the Dana Farber Cancer Institute.

Condition Intervention Phase
Plasma Cell Disorder
Drug: Lenalidomide
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Official Title: Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias

Resource links provided by NLM:

Further study details as provided by Boston VA Research Institute, Inc.:

Primary Outcome Measures:
  • Positive for Hepatitis B Surface Antigen [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    The number of participants who test positive for the antibody titer against hepatitis B surface antigen (HbSAg).

Secondary Outcome Measures:
  • Safety [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
    Number of participants with adverse events as a measure of safety and tolerability

  • Quantity of Subjects With a T-cell Response [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Participants who displayed a T cell responses against HbSAg following vaccination

  • Phenotypic Changes [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Phenotypic changes in peripheral blood cells following CC-5013 (lenalidomide) administration especially in regards to CD3, CD4, CD8 T cells, and NK and NKT cells.

Enrollment: 38
Study Start Date: April 2005
Study Completion Date: April 2014
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lenalidomide
Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
Drug: Lenalidomide
Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
Other Names:
  • CC-5013
  • Revlimid
Placebo Comparator: Placebo
Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
Drug: Placebo
Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
Other Name: Sugar pill

Detailed Description:

The primary object of this study is to evaluate the effect of CC-5013 on the response to hepatitis B vaccine in myeloma. Secondary objectives include the evaluation of immunologic and functional genomic changes following CC-55013.

This study will be a two-center, randomized, double-blinded, placebo-controlled trial. A single dose of Hepatitis B vaccine will be administered to subjects. CC-5013 or placebo will be administered for 7 days prior to and 7 days after the vaccine. Collection of samples for immune analysis will be performed prior to the initiation of CC-5013 administration, at the time of vaccination, and 7, 14, and 28 days after vaccination. Safety assessment will be performed at each visit.

Primary Endpoint

  • Titer of antibodies to hepatitis B virus Secondary Endpoints
  • Immune analysis
  • Hepatitis B related T cell response
  • Safety profile

All the patients should not have a prior response against hepatitis B surface antigen. The study will be comprised of 64 multiple myeloma patients who have not taken any therapeutic agents in the 30 days prior to enrollment in the study. Subjects will be randomly assigned to receive or not receive CC-5013, and all will be vaccinated. The study is designed to detect a biological difference of 50% with an alpha of 0.05 and a beta of 0.8.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Understand and voluntarily sign an informed consent form.
  • Age > = 18 years at the time of signing the informed consent form.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Must have confirmed diagnosis of plasma cell disorder.
  • Patients with prior thalidomide or CC-5013 (lenalidomide) use are eligible but these agents must have been discontinued at least 4 weeks prior to treatment in this study.
  • All previous cancer therapy, including chemotherapy, and dexamethsone must have been discontinued at least 4 weeks prior to treatment in this study. Patients with recent radiation, hormonal therapy and surgery are eligible.
  • Patients must not have received prior Hepatitis B vaccination.
  • Patient should be negative for antibody against HbSAg.
  • ANC >= 1000, Platelets >= 75,000.
  • Women of childbearing potential (WCBP) must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active WCBP must agree to use two of the following adequate forms of contraception throughout the entire study (tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). A WCBP must agree to have pregnancy tests 4 weeks after her last dose of lenalidomide. Due to the short duration of drug therapy, abstinence would also be a reasonable option.

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  • Pregnant or lactating females.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Use of any other experimental drug or therapy within 28 days of baseline.
  • Known hypersensitivity to thalidomide.
  • The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
  • Concurrent use of other anti-cancer agents or treatments.
  • Known HIV, HBV and HCV positivity.
  • Clinically significant autoimmune disease.
  • Serious intercurrent illness such as active infection requiring IV antibiotics, significant cardiac or pulmonary disease.
  • Psychiatric disorder, alcohol or illicit drug use.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02041325

United States, Massachusetts
VA Boston Healthcare System
Boston, Massachusetts, United States, 02130
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Boston VA Research Institute, Inc.
Dana-Farber Cancer Institute
Principal Investigator: Nikhil C Munshi, M.D. VA Boston Healthcare System; Harvard Medical School; Dana-Farber Cancer Institute
  More Information

Responsible Party: Nikhil Munshi, M.D., Associate Professor of Medicine Harvard Medical School; Physician, Boston VA Research Institute, Inc. Identifier: NCT02041325     History of Changes
Other Study ID Numbers: IRB 1831 
Study First Received: January 14, 2014
Results First Received: February 9, 2016
Last Updated: April 10, 2016
Health Authority: United States: Food and Drug Administration
United States: VA Boston Healthcare System Human Studies Subcommittee
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Virus Diseases
Liver Diseases
Digestive System Diseases
Blood Protein Disorders
Hematologic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Hepatitis B
Multiple Myeloma
Neoplasms, Plasma Cell
Hepadnaviridae Infections
DNA Virus Infections
Hepatitis, Viral, Human
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances processed this record on October 21, 2016